Navigation Links
Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
Date:10/30/2013

CAMBRIDGE, Mass., Oct. 30, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results of a global, Phase 2, open-label, randomized study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.

This study did not meet the primary endpoint of progression free survival in the overall population.  The hazard ratio (HR) for progression free survival (PFS) was 1.0 [95% CI 0.74 - 1.4].

Ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel. When using a combination of two biomarkers, the hazard ratio for PFS was 0.37 [95% CI 0.2 - 0.8] in the 34% of patients who were biomarker positive. The hazard ratio for PFS in the biomarker negative population was 1.54 [95% CI 1.0 - 2.4].

An overall increase in all grades of gastrointestinal toxicities, including diarrhea (73.6% vs. 42.5%), vomiting (31.4% vs. 18.8%) and other mucosal toxicities such as rhinitis (7.1% vs. 1.3%), epistaxis (23.6% vs. 17.5%), stomatitis (22.1% vs. 10.0%) and mucosal inflammation (22.1% vs. 1.3%), were observed in the combination as compared to paclitaxel alone, the majority of which were mild to moderate in severity. An increase in the pulmonary embolism rate was observed with the combination of MM-121 and paclitaxel (5.0% vs. 1.2%). No enhancement of paclitaxel-related peripheral neuropathy was reported with the combination.

"This unique study design lays the groundwork for future translational studies in ovarian cancer. The rapid enrollment into this study was a testament to the commitment of patients and physicians to advance our knowledge and improve upon available therapies i
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
5. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
6. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
7. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
9. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
10. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
11. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... ARBOR, Mich. , Oct. 31, 2014 /PRNewswire/ ... immune modulators to treat autoimmune disease and cancer, ... of novel synthetic RORgamma agonist product candidates will ... Society for Immunotherapy of Cancer (SITC) being held ... & Convention Center, National Harbor, MD.  The poster, ...
(Date:10/31/2014)... 31, 2014 ThynkWare ( www.thynkware.com ) is ... text and email messages using their thoughts. ... by ThynkWare,s founder, Duane Cash , which is ... This technology allows users to control their devices in ... thought. ThynkWare provides the interface layer between ...
Breaking Medicine Technology:Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2
... SALT LAKE CITY, Dec. 14, 2011 Lineagen, Inc., ... linked disorders, and Fast Forward, LLC, a nonprofit subsidiary ... alliance to fund the clinical development and validation of ... of the program is to develop a test that ...
... 2011 Carl Zeiss Group continues to ...   - Vision Care business group fully consolidated ... of global economic uncertainty Carl Zeiss has ... the company generated revenues of EUR 4.237b (prior year: EUR ...
Cached Medicine Technology:Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4Carl Zeiss: Revenue Tops Four Billion Euro Mark for Very First Time 2
(Date:10/31/2014)... for low back pain caused by spinal stenosis varies ... a new report says. "Nearly 80 percent of ... in their lives, and about 30 million people a ... co-author Brook Martin, of the Dartmouth Institute of Health ... release. In spinal stenosis, thickening of tissue surrounding ...
(Date:10/31/2014)... IL – New research suggests that insomnia is a ... and other unintentional fatal injuries. The results underscore the ... the National Healthy Sleep Awareness Project. , Results show ... a dose-dependent manner with the number of insomnia symptoms ... 2.8 times more likely to die from a fatal ...
(Date:10/31/2014)... The Suspension Revolution review published by Daily Gossip ... Dan Long, a suspension training specialist. , Long ... life coach. The author of this program claims that ... impossible , The Suspension Revolution review reveals that this ... efficiency when it comes to burning fat, building muscles, ...
(Date:10/31/2014)... Florida Air Academy, the Melbourne ... grades 6-12, is taking the lead when it ... concussions, becoming the first high school in central ... Assessment and Cognitive Testing) computerized assessment to all ... grabs the headlines, and the Centers for Disease ...
(Date:10/31/2014)... Phoenix dentist , Dr. Christy, is ... Whether patients simply need routine care or have a more ... now to get that necessary care. The right dental treatments ... and even essential treatments due to financial concerns. Throughout the ... any treatments offered by the team at Christy Dental Care. ...
Breaking Medicine News(10 mins):Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... has a significant association with feelings of external pressure ... girls, especially those who are white, suggests a research ... Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting ... Results show that pressures to have a thin body ...
... cutting-edge research that promises to revolutionise the diagnosis and treatment ... used in the long-term to develop a radical new type ... dummy to meet the different needs of individual patients. If ... market within 4 years. The research is being ...
... breakthrough by researchers at the Institut de recherches cliniques de ... a scientific journal of the Cell Press group. Led ... new requirement for the proper functioning of the Sonic Hedgehog ... proteins that gives cells the information needed for the embryo ...
... Gordon HealthDay Reporter , MONDAY, June 13 (HealthDay News) ... the park may depend on the time of the game, and ... night owl. New research on Major League Baseball players suggests ... game starts before 2 p.m., while night owls are at their ...
... Western Reserve University School of Medicine have discovered a ... to chronic health problems. If they learn to ... macrophages, "We have a shot at a novel treatment ... disease and cancer," said Mukesh K. Jain, MD, Ellery ...
... A new study published by the American Physiological Society ... 2 diabetes can begin in the womb, giving new ... disease at the center of a worldwide epidemic. The ... are even moderately undernourished while pregnant and breastfeeding, their ...
Cached Medicine News:Health News:White adolescent girls may be losing sleep from the pressure to be thin 2Health News:New software 'hearing dummies' pave the way for tailor-made hearing aids 2Health News:New software 'hearing dummies' pave the way for tailor-made hearing aids 3Health News:A scientific breakthrough at the IRCM could help understand certain cancers 2Health News:Hey, Batter: Your Sleep Habit May Affect Your Swing 2Health News:Hey, Batter: Your Sleep Habit May Affect Your Swing 3Health News:Genetic factor controls health-harming inflammation in obese 2Health News:Undernourishment in pregnant, lactating females found key to next generation's disease 2Health News:Undernourishment in pregnant, lactating females found key to next generation's disease 3
15mm Open Blades, Thumb Screw Control; in Titanium....
10mm from mid screw to tips; curved tips, in Titanium....
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel....
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
Medicine Products: